DGAP-News: Scenic Biotech BV: Scenic Biotech Appoints Dr. Philippe Dro as Independent Chairman
Scenic Biotech BV: Scenic Biotech Appoints Dr. Philippe Dro as Independent Chairman
02.02.2021 / 09:30
PRESS RELEASE
- Dr. Philippe Dro brings entrepreneurial expertise and biotech, medtech and pharma industry experience
- Successful serial entrepreneur with track record of growing companies, notably for Themis and Glycovaxyn
- Joins at a key juncture in Scenic Biotech s strategic growth, building its pipeline of genetic modifier drug candidates
Amsterdam, The Netherlands, 2 February, 2021 - Scenic Biotech BV ( Scenic ), a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, today announced that it has appointed Dr. Philippe Dro as its independent Chairman. A highly experienced entrepreneur, he replaces Dr. Ulrich Grau who retires from the Board of Directors.
Philippe Dro brings entrepreneurial expertise and biotech, medtech and pharma industry experience
Successful serial entrepreneur with track record of growing companies, notably for Themis and GlycoVaxyn
Joins at a key juncture in Scenic Biotech’s strategic growth, building its pipeline of genetic modifier drug candidates
AMSTERDAM, The Netherlands, February 02, 2021 / B3C newswire / Scenic Biotech BV (“Scenic”), a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, today announced that it has appointed Dr. Philippe Dro as its independent Chairman. A highly experienced entrepreneur, he replaces Dr. Ulrich Grau who retires from the Board of Directors.